BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther. 2002;16:1811-1817. [PMID: 12269976 DOI: 10.1046/j.1365-2036.2002.01348.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opinion on Pharmacotherapy 2005;5:137-49. [DOI: 10.1517/14656566.5.1.137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
2 Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment Pharmacol Ther Symp Series 2006;2:315-26. [DOI: 10.1111/j.1746-6342.2006.00062.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Yamagishi H, Koike T, Ohara S, Horii T, Kikuchi R, Kobayashi S, Abe Y, Iijima K, Imatani A, Suzuki K, Hishinuma T, Goto J, Shimosegawa T. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole. World J Gastroenterol 2008; 14(15): 2406-2410 [PMID: 18416470 DOI: 10.3748/wjg.14.2406] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sugimoto M, Yamaoka Y. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2018;9:1560. [PMID: 30697158 DOI: 10.3389/fphar.2018.01560] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
5 Sugimoto M, Jang JS, Yoshizawa Y, Osawa S, Sugimoto K, Sato Y, Furuta T. Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review. Diagn Ther Endosc. 2012;2012:791873. [PMID: 22851882 DOI: 10.1155/2012/791873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
6 Kagawa T, Iwamuro M, Ishikawa S, Ishida M, Kuraoka S, Sasaki K, Sakakihara I, Izumikawa K, Yamamoto K, Takahashi S. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther. 2016;44:583-591. [PMID: 27464849 DOI: 10.1111/apt.13747] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
7 Kuwayama H, Asaka M, Sugiyama T, Fukuda Y, Aoyama N, Hirai Y, Fujioka T. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment Pharmacol Ther. 2007;25:1105-1113. [PMID: 17439512 DOI: 10.1111/j.1365-2036.2007.03298.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T. Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype. Dig Dis Sci 2008;53:933-7. [DOI: 10.1007/s10620-007-9965-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
9 Ahmed TA, El-Say KM. Development of alginate-reinforced chitosan nanoparticles utilizing W/O nanoemulsification/internal crosslinking technique for transdermal delivery of rabeprazole. Life Sci 2014;110:35-43. [PMID: 24997393 DOI: 10.1016/j.lfs.2014.06.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
10 Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol. 2003;18:1034-1038. [PMID: 12911659 DOI: 10.1046/j.1440-1746.2003.03126.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
11 Adachi K, Hashimoto T, Ishihara S, Fujishiro H, Sato S, Sato H, Amano Y, Hattori S, Kinoshita Y. Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment. Curr Ther Res Clin Exp 2003;64:412-21. [PMID: 24944392 DOI: 10.1016/S0011-393X(03)00120-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
13 Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opinion on Pharmacotherapy 2005;4:253-64. [DOI: 10.1517/14656566.4.2.253] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
14 Manes G, Pieramico O, Perri F, Vaira D, Giardullo N, Romano M, Nardone G, Balzano A. Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci. 2005;50:443-448. [PMID: 15810623 DOI: 10.1007/s10620-005-2455-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
15 Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH. The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. Gut Liver. 2010;4:201-206. [PMID: 20559522 DOI: 10.5009/gnl.2010.4.2.201] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
16 Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Review of Anti-infective Therapy 2014;3:863-70. [DOI: 10.1586/14787210.3.6.863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
17 Qasim A, O’morain CA, O’connor HJ. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration. Fundamental & Clinical Pharmacology 2009;23:43-52. [DOI: 10.1111/j.1472-8206.2008.00635.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
18 Calvet X, Gomollón F. What is potent acid inhibition, and how can it be achieved? Drugs. 2005;65 Suppl 1:13-23. [PMID: 16335854 DOI: 10.2165/00003495-200565001-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
19 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 15.7] [Reference Citation Analysis]
20 de Korwin J, Ducrotté P, Vallot T. Les nouveaux inhibiteurs de la pompe à protons, un progrès dans la prise en charge des maladies acido-peptiques ? La Presse Médicale 2004;33:746-54. [DOI: 10.1016/s0755-4982(04)98731-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007;8:1199-1210. [PMID: 17924835 DOI: 10.2217/14622416.8.9.1199] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
22 Nishizawa T, Suzuki H, Nakagawa I, Iwasaki E, Masaoka T, Hibi T. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2008;23 Suppl 2:S167-S170. [PMID: 19120892 DOI: 10.1111/j.1440-1746.2008.05407.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
23 Varannes SBD, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting. World J Gastroenterol 2006; 12(16): 2569-2573 [PMID: 16688803 DOI: 10.3748/wjg.v12.i16.2569] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
24 Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol 2009; 15(8): 990-995 [PMID: 19248200 DOI: 10.3748/wjg.15.990] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ando T, Kato H, Sugimoto N, Nagao Y, Seto N, Hongo H, Kajikawa H, Isozaki Y, Shimozawa M, Naito Y, Yoshida N, Ishizaki T, Yoshikawa T. A Comparative Study on Endoscopic Ulcer Healing of Omeprazole Versus Rabeprazole with Respect to CYP2C19 Genotypic Differences. Dig Dis Sci 2005;50:1625-31. [DOI: 10.1007/s10620-005-2907-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
26 Lim SL, Goh WT, Lee JM, Ng TP, Ho KY. Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol. 2005;20:995-1001. [PMID: 15955205 DOI: 10.1111/j.1440-1746.2005.04167.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
27 Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23:746-751. [PMID: 18028348 DOI: 10.1111/j.1440-1746.2007.05218.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
28 Cavallari LH, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med 2011;4:123-36. [PMID: 23226058 DOI: 10.2147/PGPM.S15497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
29 Ishida Y, Goto Y, Kondo T, Kurata M, Nishio K, Kawai S, Osafune T, Naito M, Hamajima N. Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A. Int J Med Sci. 2006;3:135-140. [PMID: 17003844 DOI: 10.7150/ijms.3.135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
30 Choi KD, Kim N, Jang I, Park YS, Cho JY, Kim J, Shin JM, Jung HC, Song IS. Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea. Journal of Gastroenterology and Hepatology 2009;24:1617-24. [DOI: 10.1111/j.1440-1746.2009.05939.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
31 Yoon SB, Park JM, Lee JY, Baeg MK, Lim CH, Kim JS, Cho YK, Lee IS, Kim SW, Choi MG. Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates. World J Gastroenterol 2014; 20(4): 1061-1066 [PMID: 24574779 DOI: 10.3748/wjg.v20.i4.1061] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
32 Patel KK, Babyatsky MW. Medical education: a key partner in realizing personalized medicine in gastroenterology. Gastroenterology. 2008;134:656-661. [PMID: 18325381 DOI: 10.1053/j.gastro.2008.01.064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
33 Takeshima F, Hashiguchi K, Onitsuka Y, Tanigawa K, Minami H, Matsushima K, Akazawa Y, Shiozawa K, Yamaguchi N, Taura N. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life. Med Sci Monit. 2015;21:4111-4121. [PMID: 26719012 DOI: 10.12659/MSM.895346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
34 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Reference Citation Analysis]
35 Lim P, Goh K. Review Article: Efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19:S61-8. [DOI: 10.1111/j.1440-1746.2004.03592.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Yamagishi H, Koike T, Ohara S, Horii T, Kikuchi R, Kobayashi S, Abe Y, Iijima K, Imatani A, Suzuki K, Hishinuma T, Goto J, Shimosegawa T. Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers. World J Gastroenterol 2008; 14(13): 2049-2054 [PMID: 18395905 DOI: 10.3748/wjg.14.2049] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
37 Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol 2019; 25(34): 5097-5104 [PMID: 31558859 DOI: 10.3748/wjg.v25.i34.5097] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
38 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
39 Mizokami Y. Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan. World J Gastroenterol 2009; 15(40): 5097-5102 [PMID: 19860005 DOI: 10.3748/wjg.15.5097] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
40 Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719-730. [PMID: 26193978 DOI: 10.1111/apt.13325] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 24.3] [Reference Citation Analysis]
41 Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther. 2004;20:899-907. [PMID: 15479362 DOI: 10.1111/j.1365-2036.2004.02176.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
42 Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2014;29:487-493. [PMID: 24224808 DOI: 10.1111/jgh.12442] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
43 Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709-715. [PMID: 15924600 DOI: 10.1111/j.1368-5031.2005.00517.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
44 Ohkuma K, Iida H, Inoh Y, Kanoshima K, Ohkubo H, Nonaka T, Fujita K, Kusakabe A, Inamori M, Nakajima A. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr 2018;63:80-3. [PMID: 30087548 DOI: 10.3164/jcbn.17-128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
45 Nagahara A, Suzuki T, Nagata N, Sugai N, Takeuchi Y, Sakurai K, Miyamoto M, Inoue K, Akiyama J, Mabe K. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis. J Gastroenterol. 2014;49:1536-1547. [PMID: 24366288 DOI: 10.1007/s00535-013-0925-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
46 Furuta K, Kohata Y, Fujiwara Y, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Furuta T, Nio K, Iwakiri R, Inamori M, Kawamura O, Kusano M, Kato M, Kawami N, Iwakiri K, Takeuchi T, Higuchi K, Aimi M, Naora K, Fujimoto K, Arakawa T, Kinoshita Y. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. J Clin Biochem Nutr 2014;55:178-83. [PMID: 25411523 DOI: 10.3164/jcbn.14-41] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
47 Kinoshita Y. Review article: treatment for gastro-oesophageal reflux disease - lifestyle advice and medication: REVIEW: GERD - LIFESTYLE AND MEDICATION. Alimentary Pharmacology & Therapeutics 2004;20:19-23. [DOI: 10.1111/j.1365-2036.2004.02223.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
48 Oda K, Iwakiri R, Hara M, Watanabe K, Danjo A, Shimoda R, Kikkawa A, Ootani A, Sakata H, Tsunada S. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci. 2005;50:1921-1926. [PMID: 16187198 DOI: 10.1007/s10620-005-2962-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
49 Nagahara A, Hojo M, Asaoka D, Watanabe S. Maintenance therapy of gastroesophageal reflux disease. Clin J Gastroenterol 2010;3:61-8. [PMID: 26189996 DOI: 10.1007/s12328-010-0139-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J, Matsubara Y, Miwa J, Yakabi K. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012;47:276-83. [DOI: 10.1007/s00535-011-0487-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
51 Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18:1392-1398. [PMID: 14675268 DOI: 10.1046/j.1440-1746.2003.03190.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
52 Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. Aliment Pharmacol Ther. 2004;20 Suppl 6:11-19. [PMID: 15496214 DOI: 10.1111/j.1365-2036.2004.02161.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
53 Baeg MK, Choi M, Moon SJ, Lim C, Kim JS, Cho YK, Park JM, Lee IS, Kim SW, Choi KY. Preprocedural Rabeprazole Treatment Before Endoscopic Submucosal Dissection for Gastric Neoplasms. Dig Dis Sci 2014;59:2243-8. [DOI: 10.1007/s10620-014-3117-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Ohya TR, Endo H, Kawagoe K, Yanagawa T, Hanawa K, Ohata K, Asayama M, Hisatomi K, Teratani T, Gunji T, Sato H, Matsuhashi N. A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers. World J Gastrointest Endosc 2010; 2(1): 36-40 [PMID: 21160677 DOI: 10.4253/wjge.v2.i1.36] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
55 Nakajima S, Inoue H, Inoue T, Maruoka Y. Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy: Multi-resistant Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2012;27:108-11. [DOI: 10.1111/j.1440-1746.2012.07069.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
56 Furuta K, Adachi K, Ohara S, Morita T, Tanimura T, Koshino K, Kinoshita Y. Relationship between the Acid-Inhibitory Effects of Two Proton Pump Inhibitors and CYP2C19 Genotype in Japanese Subjects: A Randomized Two-Way Crossover Study. J Int Med Res 2010;38:1473-83. [DOI: 10.1177/147323001003800430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
57 Iida H, Kato S, Sekino Y, Sakai E, Uchiyama T, Endo H, Hosono K, Sakamoto Y, Fujita K, Yoneda M, Koide T, Takahashi H, Tokoro C, Goto A, Abe Y, Kobayashi N, Kubota K, Gotoh E, Maeda S, Nakajima A, Inamori M. Early effects of oral administration of omeprazole and roxatidine on intragastric pH. J Zhejiang Univ Sci B 2012;13:29-34. [PMID: 22205617 DOI: 10.1631/jzus.B1100078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]